BioCentury
ARTICLE | Company News

Avantogen Oncology, RESprotect, SciClone deal

April 30, 2007 7:00 AM UTC

AVTO’s Resistys Inc. subsidiary granted SCLN exclusive rights to develop and commercialize RP101 in the U.S. and Canada to treat cancer. RP101, which inhibits induced chemoresistance and enhances che...